Omexa Formulary Profile
Key Indicators
- Authorised Capital ₹ 3.50 Cr
- Paid Up Capital ₹ 3.40 Cr
- Company Age 1 Year 7 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.37 Cr
About Omexa Formulary
Omexa Formulary Private Limited (OFPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 June 2023 (One year and seven months 27 days old ). Its registered office is in Bathinda, Punjab, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.50 Cr and a paid-up capital of Rs 3.40 Cr.
The company has closed loans amounting to ₹1.37 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ekambaranathan Ramanathan, Ashu Singla, and Nathan Ramanathan serve as directors at the Company.
Company Details
-
Location
Bathinda, Punjab, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U21001PB2023PTC058767
-
Company No.
058767
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Jun 2023
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Omexa Formulary?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ekambaranathan Ramanathan
|
Director | 08-Jun-2023 | Current |
|
Ashu Singla
|
Director | 09-Sep-2023 | Current |
Nathan Ramanathan
|
Director | 10-Oct-2023 | Current |
Financial Performance of Omexa Formulary.
Enhance accessibility to Omexa Formulary's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Omexa Formulary?
Unlock access to Omexa Formulary's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Glofresh Private LimitedEkambaranathan Ramanathan and Ashu Singla are mutual person
Charges (Loans)
₹0
₹1.37 Cr
Charges Breakdown by Lending Institutions
- Others : 1.37 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Oct 2023 | Others | ₹1.37 Cr | Satisfied |
How Many Employees Work at Omexa Formulary?
Unlock and access historical data on people associated with Omexa Formulary, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Omexa Formulary, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Omexa Formulary's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
